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Abstract 
Background: Guidelines in several European countries recommend standby emergency treatment (SBET) for 
travellers to regions with low or medium malaria transmission instead of continuous chemoprophylaxis: travellers are 
advised to seek medical assistance within 24 h in case of fever and to self‑administer SBET only if they are not able 
to consult a doctor within the time period specified. Data on healthcare‑seeking behaviour of febrile travellers and 
utilization of SBET is however scarce as only two studies were performed in the mid‑1990s. Since tourism is constantly 
increasing and malaria epidemiology has dramatically changed in the meantime more knowledge is urgently needed.
Methods: Some 876 travellers to destinations in South and Southeast Asia with low or medium malaria transmission 
were recruited in the travel clinic of the University Medical Center Hamburg‑Eppendorf. Demographic and travel‑
related data were collected by using questionnaires. Pre‑travel advice was carried out and SBET was prescribed in 
accordance to national guidelines. Post‑travel phone interviews were performed to assess health incidents during 
travel and individual responses of travellers to febrile illness.
Results: Out of 714 patients who were monitored, 130 (18%) reported onset of fever during travel or 14 days after 
return. Of those travellers who reported fever, 100 (80%) carried SBET during travel. The vast majority of 79 (79%) 
febrile travellers who carried SBET did not seek medical assistance. Overall, 14 (14%) febrile patients who carried SBET 
and six (20%) patients who did not carry SBET took the correct measure (doctor visit or timely SBET administration) 
as a response to febrile illness, respectively. Only two travellers self‑administered SBET, but both of them applied the 
wrong regimen.
Conclusions: In view of declining malaria transmission and improving medical infrastructure in most countries of 
Southeast Asia and obvious obstacles concerning SBET as shown in this study the current strategy should be re‑eval‑
uated. Pre‑travel advice concerning malaria in SEA should focus on appropriate mosquito bite protection and clearly 
emphasize the need to see a doctor within 24 h after onset of fever.
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Background
National recommendations for malaria prophylaxis 
for travellers to low- or intermediate-risk areas vary. 
Depending on seasonality, mode of travel, length of stay, 
travellers are advised to perform mosquito protection 
and chemoprophylaxis or carry standby emergency treat-
ment (SBET). SBET is a concept according to which trav-
ellers carry anti-malarials (e.g., atovaquone/proguanil or 
artemether/lumefantrine), which have to be self-adminis-
tered in case of fever and the inability to rule out malaria 
as the cause of fever within 24  h. The rationale behind 
the strategy of SBET is that the potential occurrence of 
side effects during continuous chemoprophylaxis might 
outweigh the relatively small risk of developing malaria 
in areas of low malaria transmission. The continuous 
decrease in malaria incidence in many low-transmission 
areas, e.g., in South- and Southeast Asia (SEA), as well as 
increasing drug resistance have also served as arguments 
in favour of SBET. The Societies for Tropical Medicine of 
Germany and Switzerland, for example, promote SBET 
for all areas of low and medium malaria transmission 
along with protection against mosquito bites instead of 
chemoprophylaxis [1]. The World Health Organization 
(WHO) recommends this approach to travellers “in some 
occupational groups who make frequent short stops in 
countries or areas with malaria risk over a prolonged 
period of time” and short-term travellers to “remote rural 
areas where there is very low risk of infection” [2]. The 
Centers for Disease Control and Prevention (CDC) in the 
USA, in contrast, recommend to carry SBET to ensure 
high-quality treatment in case of a diagnosis of malaria, 
accounting for the increasing numbers of fake anti-
malarials in some countries of SEA [3].
While the concept of SBET appears straightforward in 
theory, it is unclear whether or not travellers are willing 
or able to apply SBET correctly while being abroad. In 
fact, there has been repeated criticism that travellers may 
be unable to make correct decisions in case of onset of 
fever during travel and tend to apply medication incor-
rectly [4, 5]. To date only two publications from 1995 
are available concerning these issues. Both studies dem-
onstrated that only a small fraction of travellers had to 
self-administer SBET. Additionally, when Plasmodium 
falciparum antibody levels were assessed in all travellers 
after return it turned out that even this low number of 
self-administrations proved to be a massive overuse of 
SBET, since most SBET users had no antibodies [4, 6].
Moreover, the SBET concept is based on the assump-
tion that reliable medical care is generally not available 
at malaria-endemic tourist destinations. Yet, infrastruc-
ture for tourism, as well as medical emergency care has 
improved significantly in the past decades in many coun-
tries of SEA. At the same time, numbers of travellers 
to those regions have increased substantially due to a 
major surge in the availability of flight connections as 
well as a dramatic decrease in airline fares [7]. Concur-
rently to increased travel, malaria transmission in most 
parts of SEA has decreased, resulting in smaller num-
bers of imported malaria from the region [8, 9]. India 
also recorded a decline in malaria cases, but predomi-
nantly through control of falciparum malaria. In contrast, 
the relative proportion of Plasmodium vivax cases was 
increasing on the Indian sub-continent [10].
The aim of the present study was to assess utilization 
of SBET in the face of changing background conditions. 
Therefore, a cohort study in a population travelling to 
areas of low and medium malaria transmission in South 
Asia and SEA was performed.
Methods
Study design and recruitment
Between October 2013 and November 2014, a prospec-
tive, questionnaire-based cohort study was conducted at 
the travel clinic of the University Medical Center Ham-
burg-Eppendorf. Travellers aged ≥18 years with intention 
to travel to South Asia and SEA were screened for eligi-
bility in the waiting area prior to seeing a trained physi-
cian for travel medicine advice. The following destination 
countries were defined for participation: India, Thailand, 
Laos, Cambodia, Vietnam, Sri Lanka, Myanmar, Indone-
sia, Bangladesh, the Philippines, or Malaysia. Additional 
inclusion criteria were travel duration between 7  days 
and 12 weeks and willingness to provide contact data for 
a post-travel interview as well as signed informed con-
sent to participate. Study procedures comprised comple-
tion of a pre- and post-travel questionnaire.
Pre‑travel interview
The pre-travel questionnaire had to be completed before 
travel medicine consultation with a physician. The pre-
travel questionnaire comprised questions concerning 
the travel destination, mode of travel and basic health 
data of the participant, such as pre-existing illness and 
regular medication. To avoid a possible behavioural bias 
of study participants regarding the awareness of fever or 
application of SBET, participants were informed that a 
post-travel telephone interview would be conducted con-
cerning health incidents during and after travel without 
specifying precise question items or topics.
Standby emergency treatment was prescribed accord-
ing to the current recommendations of the German Soci-
ety of Tropical Medicine (DTG) for the years 2013/2014 
[1]. In brief, the DTG advised travellers to all countries, 
except certain regions in Indonesia, to carry out mos-
quito bite prevention at all times and to carry SBET, such 
as atovaquone/proguanil or artemether/lumefantrine. 
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For regions in Indonesia located east of Bali, travellers 
were advised to take continuous chemoprophylaxis either 
with atovaquone/proguanil or mefloquine.
Use of SBET was thoroughly explained, travellers were 
advised to take a thermometer with them and administer 
SBET only in case of fever with temperatures of >38  °C 
and if they were unable to seek medical advice within 
24  h. Fever, chills, myalgia, and symptoms suggestive 
of a common cold were mentioned as key symptoms to 
prompt travellers to seek medical advice. Additionally, 
a leaflet with all instructions was handed out to all par-
ticipants. Participation in the study did not influence rec-
ommendations of preventive measures against mosquito 
bites, vaccinations or prescription of SBET.
Post‑travel interview
Between 4 and 6  weeks after travellers had returned 
home, all participants were contacted by a trained mem-
ber of the study team to be screened for participation 
in the post-travel interview by asking the following four 
questions:
1. Did you experience fever, chills or flu-like symptoms 
during your travelling abroad or within 14 days after 
returning home?
2. Did you consult a doctor during your travelling 
abroad or within 14 days after returning home?
3. Did you or somebody from your travel group carry 
any anti-malarial medication (e.g., mefloquine, 
atovaquone/proguanil, doxycycline, artemether/
lumefantrine) or buy one in the destination country?
4. Did you self-administer any anti-malarial medica-
tion?
If one of these questions was answered with “Yes”, 
travellers qualified for participation in the detailed post-
travel questionnaire concerning symptoms, date and 
place of onset of symptoms, doctor visit, diagnosis and 
medication.
Data analysis
Data analysis was carried out by using Stata v11.1 (Stata-
Corp, College Station, TX, USA). Data analysis was 
descriptive and no statistical hypothesis was tested.
Notification data on malaria
To define the context in which standby emergency treat-
ment is currently used in Germany, notification data of 
malaria cases from the destination countries covered 
by the study were analysed. In Germany, notification of 
malaria cases by laboratories is mandatory and based on 
the direct detection of the malaria parasite in the human 
blood. The diagnosing laboratory reports directly to the 
Robert Koch Institute (RKI). A second data form with 
information on travel destinations and purposes, clini-
cal findings, prophylaxis, and treatment is completed by 
the attending physician. The department of infectious 
disease epidemiology of the RKI joins the information 
of both data forms in a unique database and analyse 
the data on an annual basis. Despite the mandatory 
nature, notification data are incomplete: not all cases are 
reported; for some cases the RKI receives only one of the 
two data forms; some of the data forms are only partially 
filled out.
Ethical considerations
The study protocol was approved by the ethics commit-
tee of the Medical Council in Hamburg, Germany. Prior 
to recruitment and pre-travel advice, eligible travellers 
were informed about the study by a member of the study 




Out of 1671 travellers screened for eligibility, pre-travel 
questionnaires were completed by 876 travellers with a 
median age of 32 years [interquartile range (IQR) 17–45]. 
Gender distribution was about equal (52.7% women). The 
majority of participants were well educated, more than 
half (53.9%) of them held a university degree. Pre-existing 
illness was reported by only a minor proportion of 14.6% 
of study participants. Thyroid disease and chronic res-
piratory diseases accounted for the most frequent disor-
ders with 2.5 and 2.1%, respectively. Cardiac disease and 
diabetes were stated by eight (0.9%) and five (0.6%) of 
travellers. More than a quarter of travellers reported car-
riage of regular medication such as contraceptives (8.6%), 
drugs related to thyroid disease (4.9%) or hypertension 
(2.8%) (Table 1).
Thailand (35.6%), Vietnam (25.5%) and Cambodia 
(20.8%) were the most popular destinations. The median 
duration of travel was 21 days (IQR: 21–28). Top reason 
for travel was tourism, almost three-quarters of travellers 
intended to travel independently, i.e., without any kind 
of guidance. Only 32.4% of study participants had never 
travelled to (sub-) tropical regions before (Table 2).
Post‑travel
Of the 876 travellers recruited before travel, 714 could 
be contacted via telephone for a post-travel interview. 
Amongst these, 130 (18.2%) reported onset of fever dur-
ing travel or within 14 days after return. Of these, 31.5% 
reported concomitant diarrhoea, 14.6% reported vomit-
ing. Myalgia, chills and other flu-like symptoms were 
reported by 47.7% (Table 3).
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SBET utilization
Overall, 511 (71.6%) travellers carried SBET during 
travel. Out of 130 febrile travellers, 100 (76.9%) carried 
SBET during travel. Amongst those febrile travellers 
who carried SBET, 21 (21%) attended a local medi-
cal care facility because of the fever, only 14 (14%) of 
those within 24 h after onset of fever. Only 2 out of 714 
travellers self-administered SBET in terms of emer-
gency medication, but did not apply the correct scheme 
(Fig.  1). A 25-year old male traveller to Malaysia and 
Indonesia stated to have mistakenly applied one tablet 
of atovaquone/proguanil during his stay in Malaysia 
due to “lack of knowledge”. After his return to Germany 
he experienced fever, chills and diarrhoea and con-
sulted a doctor who diagnosed an infection with Sal-
monella spp.
Another 45-year old traveller to India experienced 
fever, diarrhoea and flu-like symptoms on his 21st day 
of travel. He did not attend a medical facility, but self-
administered one tablet of atovaquone/proguanil seven 
days after onset of the symptoms, while he was staying in 
Kolkata/India (Table 4).
Out of 30 febrile travellers not carrying SBET during 
travel, nine (30%) visited a healthcare facility after the 
onset of fever, six of those within 24 h. Overall, 14 trav-
ellers (14%) experiencing fever during travel followed 
instructions as recommended by pre-travel advice by 
carrying SBET and visiting a health care facility within 
24 h. None of the 14 travellers visiting a clinic for fever, 
took SBET, since malaria was ruled out at the health facil-
ity. Among travellers who did not experience fever dur-
ing travel, no one self-administered SBET as emergency 
medication.
Recorded cases of imported malaria from South Asia 
and SEA
Table  5 shows the distribution of notified imported 
malaria cases from South Asia and SEA to Germany 
between 2011 and 2015. Throughout this period, most 
travellers with malaria returned from India and Indone-
sia, while no malaria was imported from Myanmar and 
Laos. The majority of notified cases was attributable to P. 
vivax infections (46.6%), while only 13 (17%) cases of P. 
falciparum were notified.
Discussion
A substantial proportion of 18% of travellers to regions 
of South Asia and SEA with medium and low risk for 
malaria transmission reported febrile illness during 
travel. Only very few travellers adhered to the pre-travel 
advice to seek medical support within 24  h in case of 
fever. Only 2 out of 714 travellers self-administered SBET 
during travel, but both of them applied an incorrect regi-
men and took a single tablet only, which would not have 
any therapeutic effect in case of true malaria. The study 
team is not aware of any case of malaria in the study 
population.
In assessing the concept of SBET, three main prob-
lems were identified in travellers with fever during travel: 
(i) a major proportion of travellers did not carry SBET 
although it was prescribed; (ii) non-adherence to pre-
travel advice while being abroad; and, (iii) incorrect self-
administration of SBET.
Travellers recruited for this study were young with a 
median age of 32  years, healthy, disproportionally well 
educated and the majority was proficient with travelling 
to (sub-) tropical countries. In this respect characteristics 
of this population are comparable to those from other 
studies and it seems justifiable to assume, that the cur-
rent results can be generalized to other traveller popula-
tions attending pre-travel clinics [11, 12].




Age (median) 32 18 (27–45)
Travellers’ characteristics n %
Sex
 Male 414 47.3
 Female 462 52.7
Education
 Tertiary degree 515 58.8
 Upper secondary degree 212 24.2
 Lower secondary degree 133 15.2
 Primary 16 1.8
Pre‑existing illness
 Any 128 14.6
  Thyroid disease 22 2.5
  Chronic respiratory diseases 18 2.1
  Allergies 13 1.5
  Hypertension 11 1.3
  Neurologic disorders 11 1.3
  Cardiac diseases 8 0.9
  Diabetes mellitus 5 0.6
  Other 61 6.9
Medication
 Any 260 26.3
  Other 95 10.8
  Contraceptive 75 8.6
  Thyroid medication 43 4.9
  Antihypertensives 25 2.8
  Antiplatelet drugs 12 1.4
  Drugs for respiratory diseases 10 1.1
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Despite the changed landscape of malaria since 1995 
when the last data on SBET utilization was published, 
the findings are in line with the prior studies. In a Swiss 
study from 1995, only six (0.5%) out of 123 febrile travel-
lers applied SBET and only four of them applied the cor-
rect regimen [4]. In a German multi-centre study, 1.4% 
(40/2867) of travellers reported SBET use. Malaria anti-
body levels were later demonstrated in four participants 
who applied SBET [6]. Increasing evidence therefore 
indicates that only a small proportion of travellers to low 
risk malaria areas adheres to pre-travel advice based on 
the SBET concept.
The low acceptance and carriage rate of SBET in this 
study population is however surprising. Only 16% of 
travellers carrying SBET took any correct measure and 
20% of travellers not carrying SBET sought medical assis-
tance after the onset of fever which is a strikingly low fig-
ure regarding the standardized pre-travel advice and the 
educational level of the study population. Explanations 
for this result may be various: available data suggest that 
the recall rate of information after medical consultations 
showed overall good results suggesting that key messages 
seem to be well captured [13–15]. Since most consulta-
tions incorporate one or more vaccinations, injection 
anxiety, which has been shown quite common in some 
populations could be a potential distractor [16, 17]. How-
ever, the only available study in this context showed no 
association between recall of information and injection 
anxiety [18]. In any case, provision of simplified key mes-
sages after vaccination may facilitate better recognition 
of information. In general, studies assessing a traveller’s 
knowledge about travel-related health issues underlined 
a general increase of knowledge after pre-travel advice, so 
that other factors are likely to have contributed to non-
adherence to emergency measures in case of fever in 
the current study [19–21]. In particular, in areas where 
population density and accessibility to medical facilities 
is good, tourists might tend to delay the decision to con-
sult a doctor in favour of waiting for spontaneous recov-
ery. Carriage of SBET could further encourage travellers 
to defer a medical consultation thereby waiting for the 
fever to drop. Challenges in adherence are not limited 
Table 2 Itinerary characteristics (n = 876)
IQR interquartile range
Itinerary characteristics IQR
Duration of travel (days) 21 7 (21–28)
Itinerary characteristics n %
Destination
 Thailand 312 35.6
 Vietnam 223 25.5
 Cambodia 182 20.8
 India 166 18.9
 Indonesia 150 17.1
 Malaysia 93 10.6
 Laos 87 9.9
 Sri Lanka 74 8.4
 Myanmar 53 6.1
 Philippines 48 5.5
Reason for travel
 Tourism 796 91.5
 Business 29 3.3
 Volunteering/education 30 3.4
 Visiting friends and relatives (VFR) 15 1.7
 Other 6 0.7
Type of travel
 Backpacking 340 38.8
 Individual travelling 306 34.9
 Organized round trip 120 13.7
 Package holiday 26 3.0
 Ship cruise 14 1.6
 No answer 70 8.0
Previous travel experience
 1–2 times 285 32.5
 3 to −5 times 169 19.3
 >5 times 134 15.3
 None 284 32.4
 No answer 4 0.5
Table 3 Symptoms of  travellers reporting fever during   
travel or 14 days after return (n = 130)
a May not sum up to 100% since some patients recalled multiple symptoms
Fever n %
Yes 130 18.2
  Uring their travel 89 68.5
  Ithin 14 days after return 41 31.5
No 559 78.3
No answer 25 3.5








Sore throat 17 13.1
Abdominal pain 15 11.5
Tiredness 12 9.2
Stomache ache 8 6.2
Flu‑like symptoms 4 3.1
Vertigo 3 2.3
Symptoms of sinusitis 3 2.3
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to the concept of SBET but are also seen for continu-
ous malaria chemoprophylaxis for travellers to high-risk 
countries [22–26]. Several studies prove that the majority 
of returning travellers with malaria did not take malaria 
chemoprophylaxis or applied an incorrect regimen, 
the majority being travellers visiting friends or relatives 
(VFR) abroad [22, 27–31].
In consequence of an expanding tourism industry, 
travel to SEA is steadily increasing. For 2014, interna-
tional tourist arrivals in the region rose to 96.7 million, 
which is a nearly fivefold increase since 1990 [7]. Con-
currently to increasing travel, malaria transmission in 
South Asia and SEA has decreased over the past years. 
Between 2000 and 2015 the estimated number of malaria 
cases and deaths for the whole WHO region Southeast 
Asia declined by 39 and 37%, respectively [32]. It has 
been argued before that the malaria risk for travellers is 
not correlated with infection rates in the local population 
and attack rates in visitors may likely be higher because 
of the absence of partial immunity in contrast to the local 
populations [33]. Recent studies confirmed the trend of 
decreasing cases of imported malaria cases from SEA [9, 
34]. According to data from malaria surveillance reports 
from the USA and 12 European countries, malaria 
cases imported from countries of SEA declined by 47% 
between 2003 and 2008 [8]. Another assessment of 320 
imported cases of malaria between 1994 and 2012 from 
Denmark showed an annual decline of 6.5% [35].
Fig. 1 Responses of travellers to febrile illness. aStand‑by emergency treatment. bDoctor visit in country of travel. cCorrect measures: febrile travel‑
lers took correct measures if they sought for medical assistance within 24 h or self‑administered SBET. dSince both travellers applied an incorrect 
scheme of SBET, administration of the medication was not counted as “correct measure”
Table 4 Febrile travellers self-administering SBET (n = 2)
Sex,  
age (years)






Male, 25 Malaysia, Indonesia Fever, chills, diarrhoea; onset after return to Germany In Germany Malaysia No
Male, 45 India Fever, diarrhoea, flu‑like symptoms; onset travel day 21 No Kolkata, India No
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However, India and Indonesia, as it is the case with 
notification data in Table  5, constitute two of the main 
source countries for imported malaria. In a retrospec-
tive analysis of national notification data from Canada, 
9.2% of imported malaria cases originated from India. 
India displayed the most common source country for 
vivax malaria cases [36]. Whilst this should be taken into 
account during pre-travel advice, the notification data to 
the RKI presented in this study show low and declining 
numbers of malaria cases imported from South and SEA 
to Germany. Indeed, these data underline the economi-
cal impact of over-prescription of SBET, if compared to 
the annual numbers of travellers to SEA. Using figures 
provided by the German Travel Association (DRV), 
1,769,825 individuals travelled to countries considered in 
this study in 2015 [37]. Considering a price of 42 Euro per 
unit, this would translate to 71.4 million Euros spent for 
SBET in 2015 in Germany alone. Facing the low number 
of imported falciparum malaria (13 cases during the past 
5 years), these expenses hardly pass any cost-benefit anal-
ysis. In the light of the decreased numbers of imported 
malaria and the fact that the majority of reported cases 
are P. vivax cases, strategies for travellers to these regions 
have to be reassessed, in particular, because relapse of 
P. vivax is not adequately prevented by regular chemo-
prophylaxis or treated by a standard regimen of standby 
emergency treatment.
Even though atovaquone/proguanil is generally con-
sidered safe, up to 82% of patients reported an adverse 
event [38, 39]. The benefit-risk ratio for continuous 
malaria chemoprophylaxis is consecutively very low for 
most regions in SEA, and does not pose a viable alterna-
tive [40]. However, data from the current study reinforce 
the assumption that SBET has to be critically assessed. 
Equipping travellers with an anti-malarial has the poten-
tial to lead to a false sense of security and an uncritical 
perception of the risk of malaria during travel, favour-
ing short-sleeved clothes and avoidance of repellents. 
Unattended administration of SBET harbours the risk of 
missing other medical conditions. The vast majority of 
travellers sojourn on popular tourist routes and visit simi-
lar places at their destinations. During the past two dec-
ades healthcare systems in most countries of South Asia 
and SEA have improved, although they remain at a low 
standard. However, from the main tourist tracks medi-
cal facilities can usually be reached within 24  h, particu-
larly in metropolitan areas. One of the male travellers in 
this study who used SBET started intake of medication in 
Kolkata, where it would easily have been possible to find a 
hospital to rule out malaria [21]. There are however argu-
ments in favour of SBET. First, travellers have advanced to 
more remote areas worldwide and carriage of SBET can 
be life-saving in cases when travellers are unable to reach 
a health facility due to missing infrastructure or external 
factors, e.g., severe weather conditions. Secondly, carriage 
of high-quality medication ensures safe treatment in view 
of increasing numbers of fake anti-malarials, especially in 
Asia [41–43]. Third, studies have shown that long-term 
travel can result in a higher cumulative risk for malaria [44, 
45]. Those travellers may benefit from provision of SBET 
Table 5 Reported cases of malaria imported into Germany from SEA between 2011 and 2014
Cases reported to the Robert Koch Institute Berlin, Germany
2011 2012 2013 2014 2015 Total
Country of travel
 Myanmar 0 0 0 0 0 0
 India 17 17 1 5 5 45
 Indonesia 4 1 1 1 2 9
 Cambodia 1 0 0 1 2 4
 Laos 0 0 0 0 0 0
 Malaysia 0 0 0 0 1 1
 Philippines 0 0 0 0 1 1
 Sri Lanka 0 0 1 0 0 1
 Thailand 0 1 3 1 2 7
 Vietnam 0 0 0 1 0 1
 Not specified 2 5 1 0 0 8
Plasmodium species
 Total (all species) 24 24 7 9 13 77
 Plasmodium falciparum 0 5 1 3 4 13
 Plasmodium vivax 18 15 4 4 5 46
 Other and non‑specified 1 1 2 1 1 6
Page 8 of 9Vinnemeier et al. Malar J  (2017) 16:44 
given the assumption that they tend to visit more rural 
regions. However, it is not possible to support this recom-
mendation with the current study data, since only individ-
uals travelling for no longer than 12 weeks were recruited.
This study has some limitations to be taken into 
account. As described above, a selective population of 
travellers visiting a health facility for pre-travel advice 
was studied. This population may not be comparable to 
the overall population travelling to South Asia and SEA. 
Earlier data demonstrated that travellers who attended a 
travel clinic have better knowledge about potential risks 
and protective measures [46]. Yet unpublished data from 
the Hamburg Airport Survey also suggest that travellers 
in the overall population have less frequently attended 
a travel clinic and are less frequently carrying SBET. 
Finally, it was not possible to completely rule out malaria 
in returned travellers, since no serology for Plasmodium 
spp. was performed. However, conduct of phone inter-
views 4–6  weeks after return makes unrecognized epi-
sodes of clinically relevant malaria unlikely.
Conclusions
Only a very small proportion of travellers to low-risk 
malaria areas experiencing fever while abroad adhered to 
pre-travel advice related to the concept of SBET. Travel 
advice concerning malaria in South Asia and SEA should 
focus on appropriate mosquito bite protection and 
clearly emphasize the need to see a doctor within 24  h 
after onset of fever. Travellers with need of SBET should 
be carefully selected. Recommendations related to SBET 
should be revisited and limited to selected situations 
only, e.g., long-term travel or travel to remote rural areas.
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